The OPTN/UNOS Policy Development Cycle: Challenges and Opportunities
Abstract The policies governing organ procurement and transplantation in the USA are developed and implemented by the Organ Procurement and Transplantation Network (OPTN) which was established by the National Organ and Transplant Act in 1984. The OPTN, operated by the United Network for Organ Sharing (UNOS), develops and revises policies through an iterative, evidence-based, consensus-driven process involving input from OPTN/UNOS committees and regions, the donation and transplant community, and the general public. Nonetheless, circumstances have arisen where the OPTN/UNOS Board of Directors has acted prior to public comment in response to urgent situations, including development of new technology, adoption of new statutes and regulations, and in response to legal challenges. These events have led to updates to the OPTN bylaws and processes to provide a more transparent framework for future actions and improve the efficiency of the OPTN policy development process. Nonetheless, opportunities for improvement remain, particularly with regard to alignment of OPTN policies with those developed by the Centers for Medicare and Medicaid Services.
This study found that liver transplant patients are at high risk of developing cardiovascular events post transplantation, even with no pre-existing risk factors. Can predictors be determined?Liver International
ConclusionsAbdominal wall defects from resection of cancerous masses of the abdominal wall can be closed with a contralateral rectus abdominis muscle transplant in the absence of mesh.
AbstractAplastic anemia (AA) has been reported to be associated with inflammatory bowel disease (IBD), but mostly with ulcerative colitis (UC). Little is known about the associations between AA and Crohn ’s disease (CD). We aim to determine the portraits of patients with AA-CD. Among a total of 657 patients with CD registered in Xijing Hospital of Digestive Diseases IBD center from January 2008 to October 2018, the patients diagnosed with concurrent AA were reviewed. Clinical presentation, medical history, endoscopic features, response to treatment, and prognosis in this set of patients were collected. Six male patie...
AbstractIncidence and outcome of microbiologically documented bacterial/viral infections and invasive fungal disease (IFD) in children and adults after hematopoietic cell transplantation (HCT) were compared in 650 children and 3200 adults in multicenter cross-sectional nationwide study. Infections were diagnosed in 60.8% children and 35.0% adults, including respectively 69.1% and 63.5% allo-HCT, and 33.1% and 20.8% auto-HCT patients. The incidence of bacterial infections was higher in children (36.0% vs 27.6%;p
Bioengineers and dentists from the UCLA School of Dentistry have developed a new hydrogel that is more porous and effective in promoting tissue repair and regeneration compared to hydrogels that are currently available. Once injected in a mouse model, the new hydrogel is shown to induce migration of naturally occurring stem cells to better promote bone healing. Current experimental applications using hydrogels and stem cells introduced into the body or expensive biological agents can come with negative side effects.The findings, published online in the journal Nature Communications, suggest that in the near future th...
Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient; Malignant Neoplasm Interventions: Drug: Nozin; Other: Best Practice Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI); Global Life Technologies Corp. Not yet recruiting
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia in Remission; Chronic Lymphocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Cytomegalovirus Positive; H ematopoietic Cell Transplant Recipient; Hodgkin Lymphoma; Lymphadenopathy; Lymphoblastic Lymphoma; Myelodysplastic Syndrome; Myelofibrosis; Myeloproliferative Neoplasm; ...
Conditions: MDS; AML Interventions: Drug: CPX-351; Drug: Daunorubicin; Drug: Cytarabine; Drug: Azacitidine Sponsor: GWT-TUD GmbH Not yet recruiting